NCT07871838Recruiting
Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer
Hypofractionated Endometrial Radiation Outcomes and Safety
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
Clinical experience with hypo fractionated radiotherapy to date has shown that it is a safe and effective way to treat many types of cancer. Hypo fractionation means that the patient receives a total of 5 radiation treatments every other day, rather than 25 treatments over 5 weeks. The goal of this study is to find out how safe this special kind of radiation technique is for women with endometrial cancer, both right after the treatment and later on. We also want to see how well this treatment works in stopping the cancer from coming back and how it affects the patients' overall health and quality of life. The main question it aims to answer is: How does this particular type of radiotherapy affect the patients in terms of short and long term side effects? Participants will: * Visit the clinic for a total of 15 times in 60 months for check ups * Complete a total of 9 questionnaires throughout the 15 visits * Have standard-of-care blood tests and imaging to monitor the cancer response to treatment
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 9 Jul 2026
- Start date
- 7 Mar 2025
- Primary completion date
- Aug 2030
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Diseases
- Endometrial cancer
- NCT number
- NCT07871838
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 7 Mar 2025 to the primary completion date, Aug 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Need of a radiotherapy field exceeding the whole pelvis.
Other illness
- Para-aortic nodal disease.
- Non-standard surgery, evidence of residual disease after surgery.
- Active inflammatory bowel disease.
- Previous cancer in the last 5 years (except non-melanoma skin cancer).
Other
- ECOG 3 or higher.
- Active scleroderma.
- Patients with contraindication to CT contrast.
- Inability to achieve dose constraints.
- Inability to reproduce simulation positioning during treatment.
Who the study is looking for
- Patients 18 years of age or older, ECOG 0-2.
- Newly diagnosed endometrial carcinoma, including endometrioid, serous, clear cell, carcinosarcoma, and dedifferentiated tumours.
- FIGO 2009 stage I-IIIC1 are eligible. 20.
- Patients will have had previous total hysterectomy + bilateral salpingo-oophorectomy + sentinel lymph node biopsy or pelvic nodal dissection, will be fully debulked (R0 resection).
- Have an indication for adjuvant pelvic radiotherapy by the attending radiation oncology physician at tumour board discussion.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McGill University Health Centre-Cedars Cancer Centre Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.